Department of Clinical Biochemistry, Pediatric Institute, Faculty of Medicine, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Department of Paediatrics, Gastroenterology and Nutrition, Pediatric Institute, Faculty of Medicine, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Biomolecules. 2021 Dec 18;11(12):1903. doi: 10.3390/biom11121903.
The increasing incidence of inflammatory bowel diseases (IBD) and the increasing severity of the course of these diseases create the need for developing new methods of therapy. The gut microbiome is extensively studied as a factor influencing the development and course of IBD. The composition of intestinal microbiota can be relatively easily modified by diet (i.e., prebiotics, mainly dietary fibers) and bacterial supplementation using beneficial bacteria strains called probiotics. Additionally, the effects of the improved microbiome could be enhanced or gained by using paraprobiotics (non-viable, inactivated bacteria or their components) and/or postbiotics (products of bacterial metabolism or equal synthetic products that beneficially modulate immunological response and inflammation). This study summarizes the recent works on prebiotics, probiotics, synbiotics (products merging pre- and probiotics), paraprobiotics and postbiotics in IBD.
炎症性肠病(IBD)的发病率不断上升,疾病的严重程度也在不断增加,这使得人们需要开发新的治疗方法。肠道微生物组作为影响 IBD 发生和发展的一个因素,受到了广泛的研究。肠道微生物群的组成可以通过饮食(即益生元,主要是膳食纤维)和补充有益细菌菌株(称为益生菌)相对容易地进行修改。此外,通过使用后生元(无生命、失活的细菌或其成分)和/或合生元(细菌代谢产物或有益调节免疫反应和炎症的等效合成产物)可以增强或获得改善的微生物组的效果。本研究总结了最近关于 IBD 中益生元、益生菌、合生菌(合并了益生元和益生菌的产品)、后生元和合生元的研究进展。